3-methyl-1-(5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 双噻吩和低聚噻吩
• 英文名称: 3-methyl-1-(5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione
• 英文别名: 3-Methyl-1-[(5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione
• 化学式: C₁₅H₁₀N₄O₂S₂
• 分子量: 342.402
• InChiKey: DAMLCAJIRVIJLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  132
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  5-(thiophene-2-yl)thieno[2,3-d]pyrimidine-4-yl amine 在 亚硝酸特丁酯 、 一水合肼 、 copper dichloride 作用下， 以 四氢呋喃 、 氯仿 、 乙腈 为溶剂， 生成 3-methyl-1-(5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione
  参考文献：
  名称：

  Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors

  摘要：

  Inactivation of the NF-kappa B signaling pathway by inhibition of IKK beta is a well-known approach to treat inflammatory diseases such as rheumatoid arthritis and cancer. Thienopyrimidine-based analogues were designed through modification of the known IKKb inhibitor, SPC-839, and then biologically evaluated. The resulting analogues had good inhibitory activity against both nitric oxide and TNF-alpha, which are well-known inflammatory responses generated by activated NF-kappa B. However, no inhibitory activity against IKK beta was observed with these compounds. The thienopyrimidine-based analogues were subsequently screened for a target kinase, and FLT3, which is a potential target for acute myeloid leukemia (AML), was identified. Thienopyrimidine-based FLT3 inhibitors showed good inhibition profiles against FLT3 under 1 mu M. Overall, these compounds represent a promising family of inhibitors for future development of a treatment for AML. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.058

文献信息

• WO2007/102679
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors
  作者：Chun-Ho Park、Chulho Lee、Jee Sun Yang、Bo-Young Joe、Kwangwoo Chun、Hyuntae Kim、Hye Yun Kim、Jong Soon Kang、Jangik I. Lee、Myung-Hwa Kim、Gyoonhee Han

  DOI：10.1016/j.bmcl.2014.04.058

  日期：2014.6

  Inactivation of the NF-kappa B signaling pathway by inhibition of IKK beta is a well-known approach to treat inflammatory diseases such as rheumatoid arthritis and cancer. Thienopyrimidine-based analogues were designed through modification of the known IKKb inhibitor, SPC-839, and then biologically evaluated. The resulting analogues had good inhibitory activity against both nitric oxide and TNF-alpha, which are well-known inflammatory responses generated by activated NF-kappa B. However, no inhibitory activity against IKK beta was observed with these compounds. The thienopyrimidine-based analogues were subsequently screened for a target kinase, and FLT3, which is a potential target for acute myeloid leukemia (AML), was identified. Thienopyrimidine-based FLT3 inhibitors showed good inhibition profiles against FLT3 under 1 mu M. Overall, these compounds represent a promising family of inhibitors for future development of a treatment for AML. (C) 2014 Elsevier Ltd. All rights reserved.